Why therapeutic response may not prolong the life of a cancer patient: Selection for oncogenic resistance

Cell Cycle

Volumn 4, Issue 12, 2005, Pages 1693-1698

  Blagosklonny, Mikhail V ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Cell cycle; Chemotherapy; Leukemia; Relapse; Remission; Stem cell

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; IMATINIB; METHOTREXATE; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; HUMAN; LIFE EXPECTANCY; REVIEW; TUMOR GROWTH;

EID: 29244479554     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.12.2259     Document Type: Review

References (74)

1. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2005; In press.
2. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994; 94:1383-9.
3. Guan Y, Hogge DE. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 2000; 14:2135-41.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11.
5. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99:319-25.
6. Ratajczak J, Kucia M, Reca R, Zhang J, Machalinski B, Ratajczak MZ. Quiescent CD34+ early erythroid progenitors are resistant to several erythropoietic 'inhibitory' cytokines; role of FLIP. Br J Haematol 2003; 123:160-9.
7. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701-7.
8. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101:3142-9.
9. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 2004; 23:7178-87.
10. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. Punish the parent not the progeny. Blood 2005; 105:1862-6.
11. Holtz MS, Forman SJ, Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005; 19:1034-41.
12. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5:275-84.
13. Wang JC, Dick JE. Cancer stem cells: Lessons from leukemia. Trends Cell Biol 2005; In press.
14. Arai F, Hirao A, Suda T. Regulation of hematopoietic stem cells by the niche. Trends Cardiovasc Med 2005; 15:75-9.
15. Glimm H, Oh IH, Eaves CJ. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood 2000; 96:4185-93.
16. Wagner W, Ansorge A, Wirkner U, Eckstein V, Schwager C, Blake J, Miesala K, Selig J, Saffrich R, Ansorge W, Ho AD. Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis. Blood 2004; 104:675-86.
17. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96:3343-56.
18. Kurzrock R, Kantarjian H, Talpaz M. Chronic myelogenous leukemia in chronic phase. Curr Treat Options Oncol 2001; 2:245-52.
19. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature 2005; 435:1267-70.
20. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105:2640-53.
21. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - comparison with historic experience. Cancer 2005; 103:2099-3108.
22. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351:657-67.
23. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17:3029-35.
24. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004; 14:43-7.
25. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99.
26. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
27. Blagosklonny MV. Cell immortality and hallmarks of cancer. Cell Cycle 2003; 2:296-9.
28. Sherr CJ. Principles of tumor suppression. Cell 2004; 116:235-46.
29. Komarova NL, Wang L. Initiation of colorectal cancer: Where do the two hits hit? Cell Cycle 2004; 3:1558-65.
30. Komarova NL. Cancer, aging and the optimal tissue design. Semin Cancer Biol 2005; 15:494-505.
31. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106:2128-37.
32. Lange T, Park B, Willis SG, Deininger MW. BCR-ABL kinase domain mutations in chronic myeloid leukemia: Not quite enough to cause resistance to imatinib therapy? Cell Cycle 2005; This issue.
33. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105:2098-8.
34. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005; 23:4100-9.
35. Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci USA 2003; 100:10002-7.
36. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nature Rev Cancer 2002; 2:221-5.
37. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332:1004-14.
38. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000; 19:3078-85.
39. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
40. Daley GQ. Gleevec resistance: Lessons for target-directed drug development. Cell Cycle 2003; 2:190-1.
41. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998; 91:1700-5.
42. Druker BJ, Tamura S, Buchdunger E, Ohno S, Gegal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 1996; 2:561-6.
43. Druker BJ. Imatinib: Paradigm or Anomaly? Cell Cycle 2004; 3:833-5.
44. Sawyers C. Targeted cancer therapy. Nature 2004; 432:294-7.
45. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101:690-8.
46. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279:34227-39.
47. Jabbour E, Hagop Kantarjian SOB, Mary Beth Rios, Lynne Abruzzo, Srdan Verstovsek, Guillermo Garcia-Manero, Jorge Cortes. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 2005; In press.
48. Blagosklonny MV. Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ 2005; 12:592-602.
49. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5:13-7.
50. Zietman AL, Dallow KC, McManus PA, Heney NM, Shipley WU. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology 1996; 47:236-9.
51. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004; 61:332-53.
52. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001; 61:4301-5.
53. Blagosklonny MV. Targeting cancer cells by exploiting their resistance. Trends Mol Med 2003; 9:307-12.
54. Blagosklonny MV. Drug-resistance enables selective killing of resistant leukemia cells: Exploiting of drug resistance instead of reversal. Leukemia 1999; 13:2031-5.
55. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 2001; 15:936-94.
56. Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000; 105:533-9.
57. 2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 2002; 21:6249-54.
58. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005; 65:1918-24.
59. 2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res 2005; 65:4401-7.
60. Stone S, Dayananth P, Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 1996; 56:3199-3202.
61. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436:720-4.
62. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 1985; 3:326-35.
63. Frei IIIrd E. Curative cancer chemotherapy. Cancer Res 1985; 45:6523-37.
64. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest 1999; 104:1655-61.
65. Cohn DE, Herzog TJ. Gestational trophoblastic diseases: New standards for therapy. Curr Opin Oncol 2000; 12:492-6.
66. Houghton JA. Apoptosis and drug response. Curr Opin Oncol 1999; 11:475-81.
67. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108:153-64.
68. Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res 2003; 63:513-21.
69. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3:17-22.
70. Holleman A, den Boer ML, Kazemier KM, Janka-Schaub GE, Pieters R. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood 2003; 102:4541-6.
71. Oudejans JJ, Harijadi A, Cillessen SA, Busson P, Tan IB, Dukers DF, Vos W, Hariwiyanto B, Middeldorp J, Meijer CJ. Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome. Mod Pathol 2005; 18:877-85.
72. ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ, Oudejans JJ. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99:4540-6.
73. Lilleyman JS. Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia. Leuk Lymphoma 1998; 31:501-6.
74. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001; 4:303-13.